The menace of noncommunicable diseases (NCDs) like cardiovascular diseases, diabetes and cancer in the developing world is increasing. These conditions disproportionally affect poverty-stricken areas. Already today 28 million people die each year from these types of diseases in low- and middle-income countries – representing nearly 75% of deaths from NCDs globally.
Today technology has huge impact on every industry. Pharmaceutical Industry is no exception. This section keeps our clients updated on the emergence of the latest technological advancements, emerging innovations and trends in Pharmaceutical industry, their impacts, advantages and other analysis as and when they occur.
Teva's unique Talent Management program facilitates early detection of employees with high potential
Our vision is to consistently develop individuals and improve overall performance to support Teva in attaining its strategy of business growth. Career development at Teva is therefore considered an essential element and perceived as a shared responsibility of managers, employees and the organization as a whole.
IMED leader one of 48 new fellows recognised for the advancement of medical science in the UK
AstraZeneca and the University of Cambridge announce new joint PhD and clinical research scholarships
AstraZeneca and the University of Cambridge today announced three new joint schemes to support more than 80 PhD scholarships and eight clinical lectureships over the next five years spanning translational science, basic and clinical research. The programmes reflect the long term commitment of AstraZeneca to the science base in the UK and the shared dedication of the company and the University of Cambridge to developing the next generation of world-class scientists.
Irish drugmaker Shire has signed a merger agreement to acquire US-based NPS Pharmaceuticals for $5.2bn.
US-based Biogen Idec is set to acquire British clinical-stage biopharmaceutical company, Convergence Pharmaceuticals.
Determined to cement access to reliable and safe sources for crucial IV drug admixtures, a growing number of hospitals are bringing production of compounded sterile products (CSPs) in-house and turning their backs on external compounding pharmacies. Such far-reaching decisions reflect the lingering distrust of outsourced CSPs, according to several administrators from hospitals that have made this move.
Global pharma major Novartis will acquire GlaxoSmithKline Plc's (GSK) cancer drugs portfolio for $16 billion and sell its vaccines business in return for $7.1 billion, apart from forming a joint venture for the consumer healthcare business in a three-part transaction.
Biotechnology firm Biocon on Friday reported a 54.51 per cent fall in its consolidated net profit at Rs 113.08 crore for the fourth quarter ended March 31, 2014.
The company had posted a net profit of Rs 248.61 crore in the same period of the previous fiscal.
Drug major Lupin has entered into a joint venture pact with Toyama-based Yoshindo Inc to form a new entity which will be responsible for development as well as obtaining marketing access for products in the Japanese market.
Page 1 of 4